{'fraction_non_alphanumeric': 0.03731343283582089, 'fraction_numerical': 0.0, 'mean_word_length': 6.16, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A Synopsis of Chromosomal Microarray Cases at Dartmouth‐Hitchcock Medical Center

Chromosomal microarrays (CMA) used to assess DNA copy number are currently considered first‐tier clinical diagnostic tests for postnatal evaluation of individuals with intellectual disability (ID), developmental delay (DD), autism spectrum disorders (ASD), and/or multiple congenital anomalies (MCA). Here, we provide a summary of the CMA cases performed at Dartmouth‐Hitchcock Medical Center during the first month that clinical CMA testing was offered.